Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

SIMPLE SUMMARY: Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma (mCRPC). Concerns of potential nephrotoxicity are based on renal tubular PSMA expression and the resulting radiophar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosar, Florian, Kochems, Niklas, Bartholomä, Mark, Maus, Stephan, Stemler, Tobias, Linxweiler, Johannes, Khreish, Fadi, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235711/
https://www.ncbi.nlm.nih.gov/pubmed/34205686
http://dx.doi.org/10.3390/cancers13123095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235711/
https://www.ncbi.nlm.nih.gov/pubmed/34205686
http://dx.doi.org/10.3390/cancers13123095

Ejemplares similares